is used to treat infertility among female patients and works by stimulating increased hormones
vital to the growth and release of mature eggs for ovulation.
Ikaclomin is available in tablet form and marketed under the brand names Clomin, Milophene
, and Omifin
Patients having difficulty becoming pregnant can take Ikaclomin on it’s own or in conjunction with Metformin
to help patients ovulate and become pregnant.
Studies show that 70% of patients who used Ikaclomin were able to ovulate, a good majority during the first months of treatment. Of that population, 15-50% were successful in becoming pregnant.
Patients are often prescribed 50 milligrams of Ikaclomin for 5 days beginning on the fifth day of their menstrual cycle
. In the event that ovulation does not occur, dosage can be increased to 100 milligrams for 5 days the month after the previous dosage. Patients should not take Ikaclomin after 6 treatment cycles.
Follow the dosing schedule set by your physician for best results. Patients should not take the medication for longer than prescribed. In the event of a missed dose, patients should immediately talk with their physician to determine the next steps. It is not recommended to take double doses to resume your dosing schedule.
For best results, physicians may look into the body temperature of the patient and ovulation tests prior to prescribing Ikaclomin.
Side effects include upset stomach
, hot flashes, pelvic fullness, headache
tenderness, or dizziness
. If these symptoms appear and persist, immediately notify your physician. The chances of a patient experiencing these side effects are low.
Change in vision, such as seeing flashes, is another possible side effect while taking Ikaclomin. This is more common when the patient is exposed to intense lighting. If a patient experiences this side effect, it may go away a couple of days after treatment. If it does not go away, consult your doctor.
Serious side effects include vaginal bleeding and changes in moods. Some patients may experience severe pain or swelling
in the pelvic area, diarrhea
, difficulty in breathing, chest pain
, irregular heartbeat
, and swelling of the legs
. If you experience any of these symptoms, consult your doctor immediately.
Before taking Ikaclomin, patients should inform their physician about any history of allergies
to medications. Patients should also consult their physician about conditions such as liver
disease, vaginal bleeding, uncontrolled thyroid, and pituitary tumor before agreeing to use Ikaclomin.
There have been cases where the use of Ikaclomin resulted in the patient having multiple births i.e. twins and triplets.
Patients are advised against engaging in activities that require mental alertness such as driving since Ikaclomin can make a person dizzy or suffer from blurred vision.
Patients should tell their physician or pharmacist about all the prescription medicines they are using before taking Ikaclomin.
Ikaclomin has the following structural formula:
• Molecular formula of ikaclomin is C26H28ClNO
• Chemical IUPAC Name is 2-[4-[(Z)-2-chloro-1,2-di(phenyl)ethenyl]phenoxy]-N,N-diethylethanamine
• Molecular weight is 405.9596 g/mol
• Ikaclomin available : 50mg tablets